February 5, 2015 / 7:20 AM / 3 years ago

AstraZeneca to buy Actavis lung drugs as Q4 earnings fall short

LONDON, Feb 5 (Reuters) - AstraZeneca said on Thursday it had agreed to buy Actavis’ branded respiratory drug business in the United States and Canada for an initial payment of $600 million as it seeks external deals to ensure growth.

The announcement came as Britain’s second-biggest drugmaker posted fourth-quarter results that fell short of expectations and said 2015 sales revenue was expected to decline by a mid single-digit percentage rate at constant exchange rates.

Core earnings per share, however, are forecast to increase by a low single-digit percent this year.

The British group, which saw off a $118 billion bid by Pfizer last year, said its sales in the fourth quarter fell 2 percent to $6.68 billion, generating core earnings down 38 percent at 76 cents a share.

Industry analysts had on average forecast sales in the quarter of $6.79 billion and earnings of 82 cents a share, according to Thomson Reuters. (Reporting by Ben Hirschler; Editing by David Holmes)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below